Sun Pharmaceutical Industries has entered into a deal to market Merck & Co's diabetes drugs - sitagliptin and sitagliptin plus metformin - in India, the two drugmakers said in a statement on Monday. Under the deal, Sun will have the rights to market the drugs only in India under different brand names, the firms said. Earlier in April, Sun and Merck formed a joint venture to develop and manufacture generic drugs for emerging markets.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Oxea is returning to its old name and its roots.
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Novo Nordisk recently announced changes to its executive leadership and Board of Directors.
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.
